Immunoglobulin News and Research

RSS

Immunoglobulin M ACE2 autoantibodies associated with severe COVID-19

As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.

19 Oct 2020

Sinopharm's candidate SARS-CoV-2 vaccine BBIBP-CorV shows promise in clinical trials

Researchers in China have conducted a phase 1/2 trial demonstrating the safety, tolerability, and immunogenicity of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

18 Oct 2020

Previous infections with seasonal coronaviruses might protect against SARS-CoV-2

Seasonal coronaviruses, which generally cause mild respiratory illness and symptoms of the common cold, belong to the same viral family as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes COVID-19.

15 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses - including several that distinguish it from other COVID-19 vaccine approaches - according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Newly identified coronavirus epitopes induce robust antibody responses

Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.

12 Oct 2020

COVID-19 survivors may have protective antibodies for 4 months

The study, published in the journal Science Immunology, highlights the body's immune response against COVID-19. Also, it offers hope that people who are infected with the SARS-CoV-2 virus will develop lasting protection against reinfection.

11 Oct 2020

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

NIH clinical trial to test a combination treatment regimen for COVID-19

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

8 Oct 2020

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Serological antibody immunoassays are one of the essential tools to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a new study, Immunoglobulin G (IgG) antibodies are detected in a large cohort, lasting up to 140 days. The researchers propose an alternative to reverse transcription-polymerase chain reaction (RT-PCR) positive status as a standard for assessing SARS-CoV-2 antibody assays and show robust performance metrics for the AbC-19 rapid test.

5 Oct 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

Computer model unravels mystery behind severe inflammation in people with COVID-19

A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation?

29 Sep 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

A recent study by French researchers has demonstrated that experimental exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) is capable of inducing mild infection in hamsters and ferrets within 7 – 10 days of exposure. However, the infection completely resolves within 14 days. The study is currently available on the bioRxiv preprint server.

28 Sep 2020

Anti-N-protein IgG may predict severity of COVID-19

A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Sep 2020

Tokyo citizens may have developed COVID-19 herd immunity, say researchers

Researchers in Japan and the United States have conducted a study showing that herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have developed among the citizens of Tokyo during the summer.

24 Sep 2020

HSS researchers use novel MRI technique to study Parsonage-Turner Syndrome

Researchers at Hospital for Special Surgery (HSS) have received a grant from the National Institutes of Health to use a novel MRI technique known as magnetic resonance neurography, or MRN, to study Parsonage-Turner Syndrome (PTS), a painful nerve disorder that leads to severe weakness.

24 Sep 2020

Study on domestic cats and dogs in COVID-19+ households

A recent survey conducted by a team of scientists from France reveals that pets living with confirmed coronavirus disease 2019 (COVID-19) patients have a high prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

23 Sep 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

Scientists identify new drug to prevent SARS-CoV-2 infection consequences

Scientists from the Department of Cell Biology of the University of Malaga and the Andalusian Centre for Nanomedicine and Biotechnology have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

19 Sep 2020